A secondary analysis of a previous study reported the result.
Men in the cohort were randomly assigned either 56 weeks of 1,000 mg intramuscular testosterone undecanoate therapy (Reandron, Bayer; n = 49; cases) or a matching placebo (n = 51; controls); 82 men completed the study. The study was conducted between April 2013 and November 2015. For the secondary analysis, primary outcomes were between-group differences during follow-up in levels of leptin, adiponectin, ghrelin, glucagon-like peptide-1, gastric inhibitory polypeptide, peptide PYY, pancreatic polypeptide and amylin.
At 56 weeks, men assigned testosterone therapy had reduced leptin levels vs. controls. Researchers noted that the between-group changes in leptin were dependent on baseline fat mass. There were no significant between-group differences for other hormones at 56 weeks, according to the researchers.
The original news report.
I have to comment that 1000 mg of testosterone a week is a huge dose, how did they ever get approval for a study like that?
Men in the cohort were randomly assigned either 56 weeks of 1,000 mg intramuscular testosterone undecanoate therapy (Reandron, Bayer; n = 49; cases) or a matching placebo (n = 51; controls); 82 men completed the study. The study was conducted between April 2013 and November 2015. For the secondary analysis, primary outcomes were between-group differences during follow-up in levels of leptin, adiponectin, ghrelin, glucagon-like peptide-1, gastric inhibitory polypeptide, peptide PYY, pancreatic polypeptide and amylin.
At 56 weeks, men assigned testosterone therapy had reduced leptin levels vs. controls. Researchers noted that the between-group changes in leptin were dependent on baseline fat mass. There were no significant between-group differences for other hormones at 56 weeks, according to the researchers.
The original news report.
I have to comment that 1000 mg of testosterone a week is a huge dose, how did they ever get approval for a study like that?